| Course | NR 565 Advanced Pharmacology Fundamentals |
|---|---|
| Week | 2 |
| Paper type | Drug class write-up |
| Length | About 1,120 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, nurse practitioner core |
| Updated | October 2026 |
Free sample paper for NR 565 Week 2
Drug Class Write-Up: Thiazide-Type Diuretics in Primary Care Hypertension, Where Chlorthalidone and Hydrochlorothiazide Part Ways and the Patients for Whom a Prescriber Reaches Past the Class
Student Name
College of Nursing, Chamberlain University
NR 565: Advanced Pharmacology Fundamentals
Instructor Name
Month Day, Year
Drug Class Write-Up: Thiazide-Type Diuretics in Primary Care Hypertension, Where Chlorthalidone and Hydrochlorothiazide Part Ways and the Patients for Whom a Prescriber Reaches Past the Class
What the Class Treats
Thiazide-type diuretics lower blood pressure by blocking sodium and chloride reabsorption in the distal convoluted tubule. In the first weeks the effect comes from reduced plasma volume; over months, volume largely returns toward baseline and the lower pressure is maintained through reduced peripheral vascular resistance. The class is one of four first-line choices for primary hypertension in adults, alongside angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and dihydropyridine calcium channel blockers (Whelton et al., 2018). In the rural clinic where I precept, a thiazide-type diuretic is the most common second agent added when a patient's pressure remains above goal on a single drug.
Where It Leads
The class is a strong first choice for Black adults without chronic kidney disease or proteinuria, for older adults with isolated systolic hypertension and for patients with edema or heart failure symptoms where a mild diuretic effect is welcome. It is also inexpensive, taken once daily and available in combination tablets. For a patient on a fixed income who already struggles with pill burden, a single combination tablet containing a thiazide and an angiotensin receptor blocker can replace two separate prescriptions.
Members Are Not Interchangeable
Hydrochlorothiazide and chlorthalidone are often written as though they were the same drug at different doses. They are not. Chlorthalidone has a half-life of roughly 40 to 60 hours, while hydrochlorothiazide's is closer to 6 to 15 hours, so chlorthalidone controls pressure across the full day and night with a single dose. At commonly used doses, chlorthalidone 12.5 to 25 mg also lowers pressure more than hydrochlorothiazide 25 mg.
That difference has not translated into fewer cardiovascular events. In a large pragmatic trial among older veterans already taking hydrochlorothiazide, switching to chlorthalidone produced no difference in major cardiovascular outcomes or noncancer deaths, while hypokalemia was more frequent with chlorthalidone (Ishani et al., 2022). The practical lesson for prescribing is that chlorthalidone is the stronger and longer-acting member, but a patient who is controlled and tolerating hydrochlorothiazide does not need to be switched.
Kidney function is the second point of separation. Thiazides were long taught to lose effect once the estimated glomerular filtration rate falls below 30 mL/min/1.73 m2. A randomized trial in patients with stage 4 chronic kidney disease and poorly controlled hypertension found that chlorthalidone lowered 24-hour ambulatory systolic pressure substantially more than placebo over 12 weeks (Agarwal et al., 2021). Chlorthalidone therefore remains an option in advanced kidney disease where hydrochlorothiazide is usually abandoned, provided potassium, creatinine and volume status are watched closely.
Indapamide, a third member, is used less often in the United States but behaves more like chlorthalidone in duration. In practice, most primary care prescribers choose between the first two.
Choosing a Starting Dose
The starting dose follows from the separation above. For a newly diagnosed adult with normal kidney function, chlorthalidone 12.5 mg each morning is a sensible start, because it gives full-day coverage at a dose that limits potassium loss. Hydrochlorothiazide 12.5 to 25 mg is reasonable when the patient needs a combination tablet that is only available with that member, or when a previous prescriber started it and the patient is controlled. Doses above chlorthalidone 25 mg or hydrochlorothiazide 50 mg add little blood pressure lowering and more metabolic effect, so a patient still above goal at those doses needs a second class rather than a higher dose. When the thiazide joins lisinopril or losartan, the pair partly offsets potassium changes in both directions, which is one reason the pairing is so common. When the patient takes a potassium supplement for another reason, that supplement should be reviewed at the first follow-up visit rather than continued by default.
The Patients It Is Wrong For
The useful half of this write-up is the list of patients for whom a prescriber reaches past the class, and for each one, what takes the job over.
A patient with gout or recurrent flares. Thiazides raise serum uric acid by reducing its renal excretion. For a patient with active gout, an angiotensin receptor blocker such as losartan, which modestly lowers uric acid, or a calcium channel blocker is a better choice.
A patient with a history of hyponatremia, particularly an older woman of low body weight or someone taking a selective serotonin reuptake inhibitor. Thiazide-associated hyponatremia can develop within weeks and present as confusion or falls. Amlodipine is the usual alternative.
A patient with poorly controlled diabetes or prediabetes on several metabolic risk drugs. Thiazides can raise glucose modestly at higher doses. Low doses are generally acceptable, but if glucose is already a struggle, a renin-angiotensin blocker, which also protects the kidney in diabetes with albuminuria, takes priority.
A patient with chronic kidney disease and albuminuria. Here the first agent should block the renin-angiotensin system for kidney protection (Whelton et al., 2018); a thiazide may still be added second.
A patient with sulfonamide-related hypersensitivity of a serious kind. Cross-reactivity is uncommon, but a patient with a past severe reaction may reasonably be offered a calcium channel blocker.
A patient who cannot return for laboratory monitoring. If a potassium and sodium check at two to four weeks is not realistic, a calcium channel blocker, which needs no routine laboratory follow-up, is safer.
Monitoring Tied to Harm
Each test has a harm attached. Serum potassium and sodium at two to four weeks after starting or increasing the dose, then at least yearly, detect hypokalemia, which raises the risk of arrhythmia, and hyponatremia, which can cause confusion and falls. Serum creatinine at the same visit detects volume depletion or a decline in kidney function, especially when a thiazide is paired with lisinopril, losartan or a similar agent. Uric acid is worth checking only in patients with a gout history. Blood pressure at home, ideally with a validated arm cuff, shows whether the dose is working between visits.
Counseling in Plain Words
The patient hears: this is a water pill that also relaxes your blood vessels; take it in the morning so you are not up at night; you may urinate more for the first week or two; call if you feel faint when you stand, have muscle cramps or weakness, or feel confused; and come back for a blood test in two to four weeks to check your salts and kidneys.
References
Agarwal, R., Sinha, A. D., Cramer, A. E., Balmes-Fenwick, M., Dickinson, J. H., Ouyang, F., & Tu, W. (2021). Chlorthalidone for hypertension in advanced chronic kidney disease. New England Journal of Medicine, 385(27), 2507-2519. https://doi.org/10.1056/NEJMoa2110730
Ishani, A., Cushman, W. C., Leatherman, S. M., Lew, R. A., Woods, P., Glassman, P. A., Taylor, A. A., Hau, C., Klint, A., Huang, G. D., Brophy, M. T., Fiore, L. D., & Ferguson, R. E. (2022). Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. New England Journal of Medicine, 387(26), 2401-2410. https://doi.org/10.1056/NEJMoa2212270
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., . . . Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
Reading the NR 565 Week 2 instructions
The drug class write-up typically asks you to describe a class of medications, how it works, when it is used and what limits it. Expect the prompt to ask for mechanism, indications, adverse effects, monitoring and patient teaching. Keep the mechanism brief and move to where the class leads and where it does not. Separate members of the class by half-life, potency, cost or effect on electrolytes, rather than treating them as one drug. Write a section on the patients for whom the class is a poor choice, and for each one, name the alternative. Attach every monitoring test to the harm it is meant to catch. End with counseling a patient could follow. Cite current guidelines and trial evidence for any comparison you draw.
How this NR 565 Week 2 example is built
The sample opens with the class's site of action and its place among four first-line options for hypertension. A short section notes who benefits most, including older adults with isolated systolic hypertension and patients who need fewer pills. The longest section separates chlorthalidone from hydrochlorothiazide: half-lives of roughly two days against less than one, a stronger effect at usual doses, a veterans trial showing no outcome difference but more hypokalemia, and evidence that chlorthalidone still works in stage 4 kidney disease. Starting doses follow. Six patient types are then listed with their alternatives, from gout to poor access to laboratory follow-up. Monitoring pairs potassium, sodium and creatinine with the harms they detect, and counseling closes the paper.
NR 565 Week 2 rubric: what full points look like
Class write-ups tend to be graded on whether they show selection within the class, whether boundaries name a replacement agent, whether monitoring is tied to harm and whether counseling is usable. The drug roster with an adverse-effect column earns the least, so this sample separates the two main members on four concrete grounds. Citing the trial that found no outcome difference shows the writer can distinguish blood pressure effect from patient benefit. The section on patients the class is wrong for carries heavy weight, and naming an alternative for each prevents it from reading as copied labeling. Monitoring linked to arrhythmia, confusion and falls shows reasoning. Plain counseling demonstrates the writer can translate the class for a patient. Formatting and APA 7 references round out the grade.
NR 565 Week 2 help from the desk
The most expensive format is the alphabetical roster of every drug in the class with a list of side effects, which gives the reader nothing to evaluate. Another frequent gap is a list of contraindications copied from labeling, with no word about what to prescribe instead. Many write-ups treat members as interchangeable and miss the chance to show selection. Monitoring sections often list tests without saying what harm each one is looking for. Counseling written in clinical terms will not help a patient. Separate the members, write the boundary section with alternatives, attach each test to a harm and finish with words a patient would recognize. If your assigned class is different, name it and the patient population you have in mind.
Get a NR 565 Week 2 example written to your instructions
Send the Week 2 instructions and the class your section assigned you, and a written example is prepared against those instructions and returned within 24 to 48 hours, the first at no cost. If your classroom supplies a table or a template, include it and the example arrives built into it.
More NR 565 papers and MSN samples
- NR 565 Week 1: Pharmacokinetics Discussion Post
- NR 565 Week 3: Prescribing Rationale
- NR 565 Week 4: Case Analysis
- NR 565 Week 5: Sample Paper, in Real Form
- NR 565 Week 6: Patient Education Handout
- NR 565 Week 7: Case Analysis
- NR 565 Week 8: Prescribing Rationale
- NR 545 Week 2: Mechanism Write-Up
- NR 509 Week 2: Documentation Assignment
- NR 507 Week 2: Case Analysis
NR 565 Week 2 questions, answered
Should the write-up cover every drug in the class?
Rarely. Two or three members compared on properties that would alter an order teach more than a complete roster, and the complete roster is what most of the section hands in. Where the classroom demands full coverage, keep that list compact and spend the remaining words on comparisons, because comparison is where the analytical points actually sit.
How much mechanism belongs in it?
Enough to explain why the class gets chosen or avoided, and no further. Mechanism written for its own sake belongs to pathophysiology, and a page of receptor detail with no prescribing consequence reads as filler in an advanced pharmacology classroom. If a sentence about the receptor changes no drug, no dose and no monitoring test, it can come out.
Where do cost and access fit?
In the boundary section, handled as clinical constraints rather than as an afterthought. A regimen the patient cannot afford or cannot keep to fails as completely as one the kidneys cannot handle, and instructors reward the write-up that says so with a named substitute attached. Vague sympathy about access with no alternative agent behind it earns nothing at all.
Where can I find a free NR 565 Week 2 sample paper?
The thiazide-type diuretic write-up above, with its comparison of chlorthalidone and hydrochlorothiazide, is the complete NR 565 Week 2 sample. A write-up on another class can be drafted on request.
Should the NR 565 Week 2 write-up compare drugs within the class?
Yes. Separating members by half-life, potency, outcome evidence or kidney function shows selection, which graders value far more than a roster.